Two dose HPV vaccine effective in treating genital warts, study finds

May 15, 2017

As of this year, kids under the age of 15 only need 2 doses of HPV vaccine. New research out of Boston Medical Center, published online in the STD Journal, is the first published clinical evidence to support new recommendations by the Center for Disease Control and Prevention (CDC) for a two-dose HPV vaccine to prevent genital warts. BMC researchers found that the two-dose human papillomavirus (HPV) vaccine provides the same level of protection against genital warts as three doses, when given as directed.

The study looked at nearly 400,000 girls from around the country to find the rate of based on the number of received. Researchers found that receiving two or three doses of the was effective. Both provided significantly more protection against genital warts than one dose or not receiving the vaccine at all.

The vaccine is recommended to prevent HPV infections and its associated diseases, including cancers and genital warts. Recently, the CDC and the World Health Organization (WHO) updated their recommendations from a three to two dose vaccine schedule for girls and boys ages 9 to 14.

"The CDC and WHO based the new two dose schedule primarily on immunogenicity results, but there was very little research on how effective that recommendation has been," said Rebecca Perkins, MD, obstetrician at BMC and the study's lead author. "This study validates the new recommendations and allows us to confidently move forward with the 2 dose schedule for the prevention of genital warts."Researchers did note that the rate of genital warts for all girls dropped significantly from 2007 to 2013 and attribute the trend to the wide distribution of the HPV vaccine in recent years.

"The data supporting a two dose schedule is encouraging, but it only reports on genital warts, not cervical dysplasia or cancer outcomes.

Collecting that long term data is paramount," said Perkins, who is also an associate professor of obstetrics and gynecology at Boston University School of Medicine. "This study will be a stepping stone for future research into the effectiveness of the two dose schedule of the HPV vaccine for other symptoms of the disease."

Explore further: Three doses of HPV vaccine recommended against genital warts

Related Stories

Three doses of HPV vaccine recommended against genital warts

February 11, 2014
Two doses of vaccine against human papillomavirus (HPV) provide good protection against genital warts, but three doses is better according to an extensive register study by researchers at Karolinska Institutet in Sweden. ...

New study shows HPV vaccine is reducing rates of genital warts

March 29, 2017
The human papillomavirus (HPV) vaccine was introduced in Australia in 2007 and New Zealand in 2008 to prevent cervical cancer. It was free for women up to age 26 in Australia and to all women under 20 in New Zealand. This ...

American Cancer Society endorses two-dose regimen for HPV vaccination

February 7, 2017
The American Cancer Society has endorsed updated recommendations on human papillomavirus (HPV) vaccination from the Advisory Committee on Immunization Practices (ACIP) supporting a two-dose schedule for boys and girls who ...

Four in ten US adults under 60 carry HPV

April 6, 2017
(HealthDay)—Nearly half of American men and women under 60 are infected with the human papillomavirus (HPV), putting them at risk for certain cancers, federal health officials reported Thursday.

HPV vaccine not protective against recurrent warts in men

November 4, 2014
(HealthDay)—The current quadrivalent human papillomavirus (HPV) vaccine does not have a significant impact on the recurrence of genital warts in men exposed to HPV infection, according to research published in the November ...

HPV vaccine effective in youth with kidney disease, but less so in those with a kidney transplant

April 7, 2016
Human papillomavirus (HPV) vaccination stimulates robust and sustained immune responses in girls and young women with chronic kidney disease (CKD) and those on dialysis, but less optimal responses to the vaccine were observed ...

Recommended for you

New compound stops progressive kidney disease in its tracks

December 7, 2017
Progressive kidney diseases, whether caused by obesity, hypertension, diabetes, or rare genetic mutations, often have the same outcome: The cells responsible for filtering the blood are destroyed. Reporting today in Science, ...

New Lyme disease tests could offer quicker, more accurate detection

December 7, 2017
New tests to detect early Lyme disease - which is increasing beyond the summer months -could replace existing tests that often do not clearly identify the infection before health problems occur.

Spinal tap needle type impacts the risk of complications

December 6, 2017
The type of needle used during a lumbar puncture makes a significant difference in the subsequent occurrence of headache, nerve irritation and hearing disturbance in patients, according to a study by Hamilton medical researchers.

Men with HPV are 20 times more likely to be reinfected after one year

December 5, 2017
A new analysis of genital human papillomavirus (HPV) in men shows that infection with one HPV type strongly increases the risk of reinfection with the same type. In fact, men who are infected with the type responsible for ...

New tuberculosis drugs possible with understanding of old antibiotic

December 5, 2017
Tuberculosis, and other life-threatening microbial diseases, could be more effectively tackled with future drugs, thanks to new research into an old antibiotic by the University of Warwick and The Francis Crick Institute.

Scientists create successful mass production system for bioengineered livers

December 5, 2017
Researchers report creating a biologically accurate mass-production platform that overcomes major barriers to bioengineering human liver tissues suitable for therapeutic transplant into people.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.